Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz)

Tomas Kauer - Moderator

Oct 1, 2024 - 04:00

Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz)

Tags:

Previous Article

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B P...

The PG&E Corporation Foundation and California Fire Foundation Announce Wildfire...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Tomas Kauer - Moderator

Related Posts

Eaton Vance stock hits 52-week high at $14.61 amid strong yearly gains

Eaton Vance stock hits 52-week high at $14.61 amid stro...

Tomas Kauer - Mode... Oct 1, 2024

Spotify back up after outage hits over 40,000 users

Spotify back up after outage hits over 40,000 users

Tomas Kauer - Mode... Sep 30, 2024

Israel says eliminates Hezbollah 'Golan Heights' member, Syrian media report Israeli airstrikes

Israel says eliminates Hezbollah 'Golan Heights' member...

Tomas Kauer - Mode... Oct 10, 2024